1. Faculty of Informatics, Engineering and Technologies, Kauno Kolegija Higher Education Institution, Lithuania , 2. SMK College of Applied Sciences, Kalvarijų, Lithuania, 3. UAB CDKjc, Kukučių, Lithuania ;
Dr. Cicenas received his BSc and MSc degrees in biology from Vilnius Pedagogical University and a PhD in biochemistry in 2004 from the University of Basel. His research interests are focused on cell signalling (protein kinases in particular) and its role in both normal cells and cancers, biomarker discovery in cancer and other proliferative disorders, and proteomics. Dr. Cicenas works at the Faculty of Informatics, Engineering and Technologies, Kauno Kolegija Higher Education Institution, as a scientist informatician. He also teaches programming at SMK College of Applied Sciences. In addition, he is a Founder and CEO of the startup CDKjc, which concentrates on kinase inhibitors and bioinformatics/biostatistics.

Department of Pharmacology, University of North Carolina at Chapel Hill, NC;
Dr. Graves received a BS in Biochemistry from Iowa State University and a PHD in Biochemistry from the University of Illinois at Champaign-Urbana. He completed post-doctoral studies with Dr. Edwin G. Krebs at the University of Washington. He is a Professor in the Department of Pharmacology where he is the Faculty Director of the Metabolomics and Proteomics Core. Over the last 30 years his lab has applied affinity-based proteomics to study drug action with a focus on protein kinases and most recently mitochondrial proteases. Using kinase inhibitor beads combined with mass spectrometry, his lab has identified kinome responses in cancer, drug resistance and other diseases. His lab has also used this technology to profile kinase inhibitor specificity in model and parasitic organisms.

Institute of Biosciences, Life Sciences Center, Vilnius University, Lithuania;
Dr. Eglė Žalytė obtained a PhD in Biochemistry in 2022. Her PhD thesis investigated molecular mechanisms that drive pancreatic cancer cell resistance to ferroptosis, a newly discovered cell death type. Currently, Dr. Žalytė works as a researcher and assistant at Vilnius University, Lithuania, as well as a researcher at the Center for Physical Sciences and Technology, Lithuania. Dr. Žalytė’s main work areas include investigation of the mechanisms of cancer cell resistance (innate and acquired), as well as the development of preclinical cancer models and anticancer therapy individualization.